Clinical Trials Logo

Type 2 Diabetic Nephropathy clinical trials

View clinical trials related to Type 2 Diabetic Nephropathy.

Filter by:
  • None
  • Page 1

NCT ID: NCT06182891 Completed - Clinical trials for Type 2 Diabetic Nephropathy

Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy

Start date: October 30, 2021
Phase: N/A
Study type: Interventional

The purpose of the real-world observational prospective study is to access the renoprotective effects of dulaglutide as well as to explore corresponding mechanisms in patients with Type 2 Diabetic Nephropathy.

NCT ID: NCT03147677 Completed - Clinical trials for Type 2 Diabetic Nephropathy

Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan

Start date: July 28, 2016
Phase: Phase 4
Study type: Interventional

This is a prospective, multi-center, randomized, open-label, parallel-arm controlled study, for which a total of 216 patients with type 2 diabetic nephropathy (Stage II-IV) will be enrolled. The subjects will be randomized to three groups in 1:1:1 ratio. One group receive Alfacalcidol 0.25ug/day and Irbesartan 150mg/day for 16 consecutive weeks. The second group receive Alfacalcidol 0.25ug/day alone for 16 consecutive weeks. The third group receive Irbesartan 150mg/day alone for 16 consecutive weeks. All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.

NCT ID: NCT01488877 Terminated - Clinical trials for Type 2 Diabetic Nephropathy

A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy

Start date: January 2012
Phase: Phase 1
Study type: Interventional

PF-03882845 is a compound proposed for treatment of type 2 diabetic nephropathy. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-03882845 in this population.

NCT ID: NCT01300273 Active, not recruiting - Clinical trials for Type 2 Diabetic Nephropathy

Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy

Start date: February 2011
Phase: Phase 4
Study type: Interventional

The investigators hypothesize that, LPD supplemented with ketoanalogs will reduce urine podocyte loss and lower the angiotensinogen level in the urine.